Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioMarin Pharmaceutical In
Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions

BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.

The company operates its business through one segment, the biopharmaceutical development and commercialization segment.

Its company's product portfolio is comprised of five approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.

Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase indicated for patients with ucopolysaccharidosis VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs.

Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase, indicated for patients with PKU, which is an inherited metabolic disease that affects patients under the age of 40 in the developed world.

Aldurazyme has been approved for marketing in the U.S., EU and other countries for patients with mucopolysaccharidosis.

Firdapse is a form of 3, 4-diaminopyridine for the treatment of Lambert Myasthenic Syndrome.

And VIMIZIM is an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.

The company was founded on March 21, 1997 and is headquartered in Novato, CA.

Number of employees : 1 681 persons.
Sales per Businesses
20132014Delta
USD (in Million)%USD (in Million)%
Biopharmaceutical Development and Commercialization548.49100%751.04100.1% +26.97%
Sales per Regions
20132014Delta
USD (in Million)%USD (in Million)%
United States277.5050.6%380.0450.7% +26.98%
Europe116.9021.3%139.9418.7% +16.47%
Rest of World76.6314%112.4915% +31.88%
Latin America67.3412.3%118.5615.8% +43.2%
Managers
NameAgeSinceTitle
Jean-Jacques Bienaimé612005Chief Executive Officer & Director
Pierre LaPalme742004Chairman
Daniel K. Spiegelman, MBA552012Chief Financial Officer & Executive Vice President
Robert A. Baffi PhD, MBA602000Executive Vice President-Technical Operations
Gordon Vehar, PhD-2008Vice President-Research
Henry J. Fuchs, MD572009Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux, MBA-2008Chief Information Officer & Vice President
Elaine J. Heron PhD, MBA672002Independent Non-Executive Director
Mike G. Grey622005Independent Non-Executive Director
Richard A. Meier552006Independent Non-Executive Director
Shareholders
NameShares%
Capital Research & Management Co. (Global Investors) 19,637,821 12.2%
Sands Capital Management LLC 11,627,607 7.25%
Fidelity Management & Research Co. 11,520,116 7.18%
The Vanguard Group, Inc. 10,593,016 6.61%
T. Rowe Price Associates, Inc. 7,997,463 4.99%
PRIMECAP Management Co. 7,992,749 4.99%
BlackRock Fund Advisors 7,356,858 4.59%
Jennison Associates LLC 5,498,822 3.43%
Baker Bros. Advisors LP 4,095,247 2.55%
SSgA Funds Management, Inc. 2,834,493 1.77%
Holdings
NameShares%Valuation
Catalyst Pharmaceuticals Inc (CPRX) 6,666,6678.13%32,933,335 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Generic Pharmaceuticals
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
SUN PHARMACEUTICA..
BIOMARIN PHARMACE..
OTSUKA HOLDINGS C..
HOSPIRA, INC.
ENDO INTERNATIONA..
ONO PHARMACEUTICA..
ASPEN PHARMACARE ..
CIPLA LTD
SHANGHAI FOSUN PH..
HANMI SCIENCE CO ..
-
SIHUAN PHARMACEUT..
CADILA HEALTHCARE..
TAISHO PHARMACEUT..
GLENMARK PHARMACE..
DIVI'S LABORATORI..
SHENZHEN SALUBRIS..
HANMIPHARM
HUNAN ER-KANG PHA..
SICHUAN KELUN PHA..
XIZANG HAISCO PHA..
Sector Pharmaceuticals
BioMarin Pharmaceutical In : Connections
Ziarco Pharma Ltd.
Rapidscan Pharma Solutions, Inc.
Reneo Pharmaceuticals, Inc.
GLyPharma Therapeutic, Inc.
Algorithme Pharma, Inc.
Balance Therapeutics, Inc.
Ziarco Group Ltd.
Biotechnology Industry Organization
Selventa, Inc.
Pediapharm Inc
Amplyx Pharmaceuticals, Inc.
A. M. Pappas & Associates LLC
Zephyrus Biosciences, Inc.
Aerogen, Inc.
Company contact information
770 street Lindaro
CA 94901 San Rafael, California
États-Unis (les)

Phone : +1 415-506-6700
Fax : +1 415-382-7889
Internet : http://www.bmrn.com
Markets and indexes
- NASDAQ All Markets
- Nasdaq Global Select Market
- Nasdaq 100 /
Stock Exchange Codes
- ISIN Code :  US09061G1013
- Bloomberg Code :  
- Reuters Code :  BMRN.O
- Datastream Code :  
© 2015 People , Fundamentals and Ownership    © 2015 Cofisem